Yew Bio Pharm Group (YEWB) 0.1850 $YEWB
Yew Bio-Pharm Group Reports 2014 Second Quarter Financial Results
PR Newswire - Thu Aug 14, 3:05PM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company"
(OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today reported financial results for the three- and six-months ended June 30, 2014.
Yew Bio-Pharm Welcomes Two New Board Members
PR Newswire - Tue Jul 15, 7:00AM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced the appointment of Tong Liu and Hengjiang (Henry) Pang to the Company's Board of Directors, effective August 1, 2014.
Yew Bio-Pharm Group Reports 2013 Fourth Quarter And Full Year Financial Results
PR Newswire - Mon Mar 31, 3:05PM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today reported financial results for the three- and twelve-months ended December 31, 2013.
Yew Bio-Pharm Chairman & CEO Issues Letter to Shareholders
PR Newswire - Thu Jan 23, 5:43PM CST
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (OTCQB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today issued the following letter to shareholders:
Yew Bio-Pharm Group Announces Coverage by S&P Capital IQ
PR Newswire - Fri Aug 23, 7:00AM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced that S&P Capital IQ has commenced coverage on Yew Bio-Pharm Group. A copy of the nine-page report, which includes an operational review, business summary, financial information, management biographies, and a sub-industry outlook, can be downloaded here: http://www.yewchina.com/En/Article.asp?Column...sTypeId=11.
S&P Capital IQ Initiates Coverage on Yew Bio-Pharm Group in Standard & Poor's Factual Stock Reports
PR Newswire - Mon Aug 19, 8:00AM CDT
S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Yew Bio-Pharm Group.
Yew Bio-Pharm Group Announces Second-Quarter 2013 Results
PR Newswire - Tue Aug 13, 3:00PM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced financial results for the second quarter ended June 30, 2013.
Yew Bio-Pharm Group Announces DTC Eligibility of Its Stock
PR Newswire - Mon Jul 22, 7:00AM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced that its shares have received electronic eligibility status from the Depository Trust Corporation (DTC) as of July 12, 2013. Trading in securities that are DTC-eligible can be electronically cleared and settled through the facilities of DTC. This fully electronic and cost-effective method of clearing securities transactions accelerates the trade settlement process for all investors and the broker/dealers that process trades in DTC-eligible securities. The Financial Industry Regulatory Authority (FINRA) previously approved the Company's stock for quotation on the Over-the-Counter Bulletin Board.
Yew Bio-Pharm Group Reports 2014 Second Quarter Financial Results
PR Newswire - Thu Aug 14, 3:05PM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company"
(OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today reported financial results for the three- and six-months ended June 30, 2014. Yew Bio-Pharm Welcomes Two New Board Members
PR Newswire - Tue Jul 15, 7:00AM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company"
(OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced the appointment of Tong Liu and Hengjiang (Henry) Pang to the Company's Board of Directors, effective August 1, 2014. Yew Bio-Pharm Group Reports 2013 Fourth Quarter And Full Year Financial Results
PR Newswire - Mon Mar 31, 3:05PM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company"
(OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today reported financial results for the three- and twelve-months ended December 31, 2013. Yew Bio-Pharm Chairman & CEO Issues Letter to Shareholders
PR Newswire - Thu Jan 23, 5:43PM CST
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company"
(OTCQB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today issued the following letter to shareholders: Yew Bio-Pharm Group Announces Coverage by S&P Capital IQ
PR Newswire - Fri Aug 23, 7:00AM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company"
(OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced that S&P Capital IQ has commenced coverage on Yew Bio-Pharm Group. A copy of the nine-page report, which includes an operational review, business summary, financial information, management biographies, and a sub-industry outlook, can be downloaded here: http://www.yewchina.com/En/Article.asp?Column...sTypeId=11. S&P Capital IQ Initiates Coverage on Yew Bio-Pharm Group in Standard & Poor's Factual Stock Reports
PR Newswire - Mon Aug 19, 8:00AM CDT
S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Yew Bio-Pharm Group.
Yew Bio-Pharm Group Announces Second-Quarter 2013 Results
PR Newswire - Tue Aug 13, 3:00PM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company"
(OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced financial results for the second quarter ended June 30, 2013. Yew Bio-Pharm Group Announces DTC Eligibility of Its Stock
PR Newswire - Mon Jul 22, 7:00AM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company"
(OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced that its shares have received electronic eligibility status from the Depository Trust Corporation (DTC) as of July 12, 2013. Trading in securities that are DTC-eligible can be electronically cleared and settled through the facilities of DTC. This fully electronic and cost-effective method of clearing securities transactions accelerates the trade settlement process for all investors and the broker/dealers that process trades in DTC-eligible securities. The Financial Industry Regulatory Authority (FINRA) previously approved the Company's stock for quotation on the Over-the-Counter Bulletin Board. 
